BRAF kinase in melanoma development and progression

Amena M. DeLuca; Archana Srinivas; Rhoda M. Alani

doi:10.1017/S1462399408000604

BRAF kinase in melanoma development and progression

Published online by Cambridge University Press: 18 February 2008

Amena M. DeLuca ,

Archana Srinivas and

Rhoda M. Alani

Show author details

Amena M. DeLuca: Affiliation:
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Archana Srinivas: Affiliation:
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rhoda M. Alani*: Affiliation:
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
*: *Corresponding author: Rhoda M. Alani, Laboratory of Cutaneous Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB 1, Suite 344, Baltimore, MD 21231-1000, USA. Tel: +1 410 614 6204; Fax: +1 410 614 5015; E-mail: [email protected]

Article contents

Abstract
References

Get access

Rights & Permissions

Abstract

Cutaneous melanoma is increasing in incidence at one of the highest rates for any form of cancer in the USA, with a current lifetime incidence of 1 in 68. Although early-stage disease is often curable, the survival rate for advanced disease is low, with an average life expectancy of 6–10 months. Knowledge of the molecular alterations associated with melanoma development and progression is expected to lead to improved therapies and outcomes. Major progress in defining the molecular alterations associated with the evolution of melanoma came in 2002, through a systematic genome-wide assessment of cancer-associated pathways. Large-scale sequencing of growth-associated genes in a variety of cancers identified a high frequency (>60%) of activating mutations of the BRAF kinase gene in human melanomas. This discovery has prompted a large number of studies evaluating the biological significance of BRAF kinase mutations in the initiation and progression of melanoma, and their importance for the development of novel melanoma therapies. Here we review the most recent studies of BRAF kinase in the pathogenesis of melanoma and their implications for defining BRAF kinase as a therapeutic point of interest in melanoma.

Type: Review Article
Information: Expert Reviews in Molecular Medicine , Volume 10 , October 2008 , e6

DOI: https://doi.org/10.1017/S1462399408000604 [Opens in a new window]
Copyright: Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Naumann, U., Eisenmann-Tappe, I. and Rapp, U.R. (1997) The role of Raf kinases in development and growth of tumors. Recent Results Cancer Res 143, 237-244CrossRef Google Scholar PubMed

2Beeram, M., Patnaik, A. and Rowinsky, E.K. (2005) Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 23, 6771-6790CrossRef Google Scholar PubMed

3Emuss, V. et al. (2005) Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 65, 9719-9726CrossRef Google Scholar

4Pritchard, C.A. et al. (1995) Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol 15, 6430-6442CrossRef Google Scholar PubMed

5Peyssonnaux, C. and Eychène, A. (2001) The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93, 53-62CrossRef Google Scholar PubMed

6Cruz, F. 3rd et al. (2003) Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63, 5761-5766Google Scholar PubMed

7Marshall, C.J. (1994) MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 4, 82-89CrossRef Google Scholar PubMed

8Kohno, M. and Pouyssegur, J. (2006) Targeting the ERK signaling pathway in cancer therapy. Ann Med 38, 200-211CrossRef Google Scholar PubMed

9Domingo, E. and Schwartz, S. Jr. (2004) BRAF. In Atlas of Genetics and Cytogenetics in Oncology and Haematology. http://AtlasGeneticsOncology.org/Genes/BRAFID828.html Google Scholar

10Davies, H. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954CrossRef Google Scholar PubMed

11Edlundh-Rose, E. et al. (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16, 471-478CrossRef Google Scholar PubMed

12Cohen, Y. et al. (2003) BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95, 625-627CrossRef Google Scholar PubMed

13Rajagopalan, H. et al. (2002) RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934CrossRef Google Scholar PubMed

14Singer, G. et al. (2003) Mutations in BRAF and KRAS characterize the development of low- grade ovarian serous carcinoma. J Natl Cancer Inst 95, 484-486CrossRef Google Scholar PubMed

15Brose, M.S. et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62, 6997-7000Google Scholar PubMed

16Wan, P.T. et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867CrossRef Google Scholar PubMed

17Jackson, S. et al. (2005) No evidence for BRAF as a melanoma/nevus susceptibility gene. Cancer Epidemiol Biomarkers Prev 14, 913-918CrossRef Google Scholar PubMed

18Meyer, P. (2003) Exclusion of BRAFV599E as a melanoma susceptibility mutation. Int J Cancer 106, 78-80CrossRef Google Scholar PubMed

19Laud, K. et al. (2003) BRAF as a melanoma susceptibility candidate gene? Cancer Res 63, 3061-3065Google Scholar PubMed

20Lang, J., Boxer, M. and MacKie, R. (2003) Absence of exon 15 BRAF germline mutations in familial melanoma. Hum Mutat 21, 327-330CrossRef Google Scholar PubMed

21Casula, M. et al. (2004) BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. J Clin Oncol 22, 286-292CrossRef Google Scholar PubMed

22Wellbrock, C. et al. (2004) V599EB-RAF is an oncogene in melanocytes. Cancer Res 64, 2338-2342CrossRef Google Scholar PubMed

23Bennett, D.C., Cooper, P.J. and Hart, I.R. (1987) A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 39, 414-418CrossRef Google Scholar PubMed

24Hingorani, S.R. et al. (2003) Suppression of BRAF (V599E) in human melanoma abrogates transformation. Cancer Res 63, 5198-5202Google Scholar PubMed

25Chudnovsky, Y. et al. (2005) Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 37, 745-749CrossRef Google Scholar PubMed

26Uribe, P., Wistuba, I.I. and Gonzalez, S. (2003) BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 25, 365-370CrossRef Google Scholar PubMed

27Pollock, P.M. et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33, 19-20CrossRef Google Scholar PubMed

28Poynter, J. et al. (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16, 267-273CrossRef Google Scholar PubMed

29Hoeflich, K.P. et al. (2006) Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66, 999-1006CrossRef Google Scholar PubMed

30Loewe, R. et al. (2004) BRAF kinase gene V599E mutation in growing melanocytic lesions. J Invest Dermatol 123, 733-736CrossRef Google Scholar PubMed

31Yazdi, A.S. et al. (2003) Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121, 1160-1162CrossRef Google Scholar PubMed

32Bevona, C. et al. (2003) Cutaneous melanomas associated with nevi. Arch Dermatol 139, 1620-1624CrossRef Google Scholar PubMed

33Kuwata, T., Kitagawa, M. and Kasuga, T. (1993) Proliferative activity of primary cutaneous melanocytic tumours. Virchows Arch A Pathol Anat Histopathol 423, 359-364CrossRef Google Scholar PubMed

34Chin, L., Merlino, G. and DePinho, R.A. (1998) Malignant melanoma: modern black plague and genetic black box. Genes Dev 12, 3467-3481CrossRef Google Scholar PubMed

35Michaloglou, C. et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724CrossRef Google Scholar PubMed

36Bennett, D.C. (2003) Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22, 3063-3069CrossRef Google Scholar PubMed

37Dong, J. et al. (2003) BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63, 3883-3885Google Scholar PubMed

38Curtin, J.A. et al. (2005) Distinct sets of genetic alterations in melanoma. New Engl J Med 353, 2135-2147CrossRef Google Scholar PubMed

39Shinozaki, M. et al. (2004) Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10, 1753-1757CrossRef Google Scholar PubMed

40Daniotti, M. et al. (2007) Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer 120, 2439-2444CrossRef Google Scholar PubMed

41Curtin, J.A. et al. (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24, 4340-4346CrossRef Google Scholar PubMed

42Libra, M. et al. (2006) Absence of BRAF gene mutation in non-melanoma skin tumors. Cell Cycle 968-970CrossRef Google Scholar PubMed

43Albino, A.P. et al. (1989) Analysis of ras oncogenes in malignant melanoma and precursor lesions: Correlation of point mutations with differentiation phenotype. Oncogene 4, 1363-1374Google Scholar PubMed

44Hocker, T., and Tsao, H. (2007) Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28, 578-588CrossRef Google Scholar PubMed

45Bauer, J. et al. (2007) Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 127, 179-182CrossRef Google Scholar PubMed

46Balch, C.M. (1992) Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 8, 400-414CrossRef Google Scholar PubMed

47Jhappan, C., Noonan, F.P. and Merlino, G. (2003) Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 22, 3099-3112CrossRef Google Scholar PubMed

48Thomas, N.E., Berwick, M. and Cordeiro-Stone, M. (2006) Could BRAF mutations in melanocytic lesions arise from dna damage induced by ultraviolet radiation? J Invest Dermatol 126, 1693-1696CrossRef Google Scholar PubMed

49Zuidervaart, W. et al. (2005) Activation of the MAPK pathway is a common even in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 92, 2032-2038CrossRef Google Scholar PubMed

50Edmunds, S.C. et al. (2003) Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 88, 1403-1405CrossRef Google Scholar PubMed

51Cohen, Y. et al. (2003) Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 44, 2876-2878CrossRef Google Scholar PubMed

52Rimoldi, D. et al. (2003) Lack of BRAF mutations in uveal melanoma. Cancer Res 63, 5712-5715Google Scholar PubMed

53Weber, A. et al. (2003) Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest 683, 1771-1776CrossRef Google Scholar

54Landi, M.T. et al. (2006) MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313, 521-522CrossRef Google Scholar PubMed

55Rees, J.L. (2004) The genetics of sun sensitivity in humans. Am J Hum Genet 75, 739-751CrossRef Google Scholar PubMed

56Fargnoli, M.C. et al. (2006) MC1R, ASIP, and DNA Repair in Sporadic and Familial Melanoma in a Mediterranean Population. J Natl Cancer Inst 98, 144-145CrossRef Google Scholar

57Kennedy, C. et al. (2001) Melanocortin 1 Receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 117, 294-300CrossRef Google Scholar PubMed

58Palmer, J.S. et al. (2000) Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 66, 176-186CrossRef Google Scholar PubMed

59Li, L. et al. (2006) Uveal melanocytes do not respond to or express receptors for alpha-melanocyte-stimulating hormone. Invest Ophthalmol Vis Sci 47, 4507-4512CrossRef Google Scholar PubMed

60Liu, W. et al. (2007) Distinct clinical and pathological features are associated with the BRAFT1799A (V600E) mutation in primary melanoma. J Invest Dermatol 127, 900-905CrossRef Google Scholar PubMed

61 (2004) The American Heritage Stedman's Medical Dictionary (2nd edn), Houghton MifflinGoogle Scholar

62Kumar, R. et al. (2003) BRAF mutations in metastatic melanoma, A possible association with clinical outcome. Clin Cancer Res 9, 3362-3368Google Scholar PubMed

63Adnane, L. et al. (2005) Sorafenib (BAY 43-9006, Nexavar^®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407, 597-612CrossRef Google Scholar

64Strumberg, D. (2005) Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today 41, 773-784CrossRef Google Scholar PubMed

65Murphy, D.A. et al. (2006) Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 169, 1875-1885CrossRef Google Scholar PubMed

66Karasarides, M. et al. (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23, 6292-6298CrossRef Google Scholar PubMed

67Strumberg, D. et al. (2006) Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 42, 548-556CrossRef Google Scholar PubMed

68Eisen, T. et al. (2006) Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis. Br J Cancer 95, 581-586CrossRef Google Scholar PubMed

69Flaherty, K.T. et al. (2004) Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol ASCO Ann Meeting Proc Suppl 22, 7507Google Scholar

70Amaravadi, R.K. et al. (2006) Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J Clin Oncol ASCO Ann Meeting Proc Suppl 24, 8009Google Scholar

71King, A.J. et al. (2006) Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 66, 11100-11105CrossRef Google Scholar PubMed

72Eisen, T. et al. (2006) Randomized Phase III trial of Sorafenib in advanced renal cell carcinoma (rcc): impact of crossover on survival. J Clin Oncol ASCO Ann Meeting Proc Suppl 24, 4524Google Scholar

73Escudier, B. et al. (2005) Randomized Phase III trial of the Raf kinase and VEGFR inhibitor Sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol ASCO Ann Meeting Proc Suppl 23, 4510Google Scholar

74Neckers, L. and Neckers, K. (2005) Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics—an update. Expert Opin Emerg Drugs 10, 137-149CrossRef Google Scholar PubMed

75Maloney, A. and Workman, P. (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2, 3-24CrossRef Google Scholar PubMed

76da RochaDias, S. Dias, S. et al. (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65, 10686-10691CrossRef Google Scholar

77Daniotti, M. et al. (2004) BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23, 5968-5977CrossRef Google Scholar PubMed

78Haqq, C. et al. (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 102, 6092-6097CrossRef Google Scholar PubMed

79Bittner, M. et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540CrossRef Google Scholar PubMed

80Seftor, E.A. et al. (2002) Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis 19, 233-246CrossRef Google Scholar PubMed

81de Wit, N.J. et al. (2002) Differentially expressed genes identified in human melanoma cell lines with different metastatic behaviour using high density oligonucleotide arrays. Melanoma Res 12, 57-69CrossRef Google Scholar PubMed

82Bloethner, S. et al. (2005) Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 26, 1224-1232CrossRef Google Scholar PubMed

83Pavey, S. et al. (2004) Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23, 4060-4067CrossRef Google Scholar PubMed

84Hoek, K.S. et al. (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19, 290-302CrossRef Google Scholar PubMed

85Jonsson, G. et al. (2007) Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 26, 4738-4748CrossRef Google Scholar PubMed

86Barnhill, R.L. et al. (1996) Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78, 427-4323.0.CO;2-G>CrossRef Google Scholar PubMed

87Thomas, N.E. et al. (2004) Tandem BRAF mutations in primary invasive melanomas. J Invest Dermatol 122, 1245-1250CrossRef Google Scholar PubMed

88Reifenberger, J. et al. (2004) Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 109, 377-384CrossRef Google Scholar PubMed

89Saldanha, G. et al. (2005) Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 12, 4499-4505CrossRef Google Scholar

90Lang, J. and MacKie, R.M. (2005) Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 125, 575-57CrossRef Google Scholar PubMed

91Omholt, K. et al. (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9, 6483-6488Google Scholar PubMed

92Maldonado, J.L. et al. (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95, 1878-1890CrossRef Google Scholar PubMed

93Davison, J.M. et al. (2005) Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 103, 788-792CrossRef Google Scholar PubMed

94Edwards, R.H. et al. (2004) Absence of BRAF mutations in UV-protected mucosal Melanomas. J Med Genet 41, 270-272CrossRef Google Scholar PubMed

95Cunningham, C.C. et al. (2000) Advances in brief: a Phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 6, 1626-1531Google Scholar

96King, A.J. et al. (2006) Demonstration of a genetic therapeutic index for tumors oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 66, 11100-11105CrossRef Google Scholar PubMed

Article contents

BRAF kinase in melanoma development and progression

Abstract

Access options

References

References

Further reading, resources and contacts

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Article contents

BRAF kinase in melanoma development and progression

Abstract

Access options

References

References

Further reading, resources and contacts

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests